Navigation Links
New Drug Could Work Against Leukemia
Date:7/2/2009

Researchers see promise for treatment of AML and other cancers

THURSDAY, July 2 (HealthDay News) -- A new targeted therapy shows promise in treating acute myeloid leukemia, a highly treatment-resistant blood cancer, according to a new study.

Researchers created an antibody (7G3) that recognizes and binds to a molecule called CD123, which is expressed at high levels on leukemia stem cells (LSCs), but not on normal blood cells. LSCs are cells that can cause acute myeloid leukemia (AML) and are critical for its long-term growth.

When AML-LSCs from human patients were transplanted into mice, those treated with 7G3 survived longer than mice that didn't receive the antibody. The researchers found that 7G3 blocked a signaling pathway in tumor cells, impaired migration of AML-LSCs to bone marrow and activated the immune system to destroy AML-LSCs.

The findings, published in the July 2 issue of the journal Cell Stem Cell, hold promise for future cancer treatments, according to the study authors.

"The recent characterization of defined populations of cancer stem cells in a range of human malignancies, as well as their relative resistance to conventional chemotherapy and radiotherapy, supports the broad applicability of our approach and provides rationale for the progression of AML-LSC-targeted therapeutics from preclinical evaluation to clinical trials," wrote Richard Lock, an associate professor at the Children's Cancer Institute Australia and the University of New South Wales, in a news release.

More information

To learn more about AML, visit the National Cancer Institute.



-- Robert Preidt



SOURCE: Cell Press, news release, July 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Monthly Pet Pill Could Kill Fleas, Ticks
2. Measurements fail to identify TB patients who could benefit from shorter treatment course
3. Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market, States Frost & Sullivan
4. Hormone Could Improve Diabetes Treatment
5. Cell Protein Could Help Spur Malignancy
6. Hundreds of Genes Could Be Linked to ADHD
7. Health-Care Reform Could Be Obamas Toughest Challenge
8. Hysterectomies Could Be Source of Stem Cells
9. ORNL finding could help electronics industry enter new phase
10. Wrong type of help from parents could worsen childs OCD
11. Report: Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Preventing Honest Disclosures
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Could Work Against Leukemia
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... and clinical outcomes, today released the podcast, “Make Plans for MACRA,” ... value-based payment into the physician's office and how physicians and other clinicians are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president ... honored by Enterprising Women magazine as one of its 2017 Enterprising Women of ... owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively support ...
(Date:4/26/2017)... JOHYNSTON, Iowa (PRWEB) , ... April 26, 2017 ... ... agriculture? DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates ... plants and help farmers produce more and better food, with fewer resources. It ...
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: